A phase 3 SOLO-1 trial found that olaparib maintenance therapy significantly improved progression-free survival (PFS) in newly diagnosed patients with advanced ovarian cancer and a BRCA1 or 2 mutation. The median PFS for those who received olaparib was approximately three years longer than the placebo group.
Research by University of Sydney reveals a link between chocolate Labrador coat color and reduced longevity, as well as higher rates of ear infections and joint conditions. The study also found that 8.8% of UK Labradors are overweight or obese.
A randomized study shows erlotinib improves progression-free survival and tumor response rate compared to gemcitabine plus cisplatin in stage IIIA-N2 EGFR-mutated NSCLC. Median progression-free survival was significantly longer with erlotinib at 21·5 months versus 11.9 months with chemotherapy.
Researchers found a link between higher levels of interleukin-10 (IL-10) and lower disease-free survival rates after radiotherapy. Elevated CRP levels, a marker of inflammation, were not associated with DFS.
A randomized, placebo-controlled study has shown that cannabis oil can produce clinical remission in up to 65% of individuals with moderately severe Crohn's disease after 8 weeks of treatment. However, the improvement does not appear to result from a dampening down of the underlying inflammatory process.
Patient-reported outcomes from NRG-RTOG 0232 show that brachytherapy alone is the superior treatment for men with intermediate risk prostate cancer, with less toxicities. The study found significant differences in clinician and patient-reported late toxicity profiles between arms.
A large comparison study found that radiotherapy to the prostate improved failure-free survival but not overall survival in men with newly diagnosed metastatic prostate cancer and a low burden of disease. The treatment was well-tolerated, with only modest side effects.
A recent study published in Canine Genetics and Epidemiology found that Labrador retrievers are prone to several health issues, including obesity and ear infections. The study analyzed data on over 33,000 Labrador retrievers and revealed that chocolate-colored Labradors are more likely to develop skin and ear problems.
The combination of avelumab and axitinib improved progression-free survival (PFS) by 6.6 months in previously untreated patients with advanced renal cell carcinoma, with confirmed objective response rates of 55.2% and 25.5%. The study's findings support the potential of this new treatment approach for patients with advanced RCC.
Researchers have developed memristors that mimic the brain's ability to process information efficiently and adapt to changing conditions. The new devices, made from niobium-doped strontium titanate, can 'forget' and retain memories, making them suitable for future electronic brains.